<DOC>
	<DOCNO>NCT01887652</DOCNO>
	<brief_summary>The purpose oh study determine usefulness anti-Mullerian hormone ( AMH ) identify woman risk excessive poor response control ovarian stimulation ( COS ) vitro fertilization ( IVF ) , clinical impact apply individualized COS strategy subsets patient .</brief_summary>
	<brief_title>Individualization Ovarian Stimulation Using AMH Maximizes Benefits Minimizes Complications Risks</brief_title>
	<detailed_description>A group 130 woman undergoing conventional COS pituitary down-regulation IVF study determine best cut-off point AMH , use receiver operate characteristic ( ROC ) analysis , discriminate excessive ( ≥20 oocyte retrieve ) poor response ( ≤4 oocyte retrieve ) . The inclusion criterion patient indication IVF treatment . Subsequently , different group 120 woman ( criterion ) assess use AMH start COS , treatment strategy individualize accord AMH result ( iCOS ) . Mild stimulation use daily dos ( 112.5 150 IU ) recombinant follicle stimulation hormone ( rec-hFSH ) rec-hFSH combine recombinant luteinizing hormone ( LH ) supplementation ( 375 IU total daily dose ) give patient identify risk excessive poor response , respectively . It evaluate : number oocyte , clinical pregnancy rate ( defined fetal heartbeat ultrasound perform 4 week transfer embryo ) occurrence Ovarian hyperstimulation syndrome ) . Outcomes compare group receive conventional iCOS use chi-square Fisher exact test .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>woman vitro fertilization treatment indication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>In Vitro Fertilization</keyword>
	<keyword>ovulation induction</keyword>
	<keyword>anti-mullerian hormone</keyword>
</DOC>